1-Bromo-2,4-dichlorobenzene | CAS:1193-72-2

We serve 1-Bromo-2,4-dichlorobenzene CAS:1193-72-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromo-2,4-dichlorobenzene

Chemical Name:1-Bromo-2,4-dichlorobenzene
CAS.NO:1193-72-2
Synonyms:1-Bromo-2,4-dichlorobenzene
2,4-Dichlorobromobenzene
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 236.8±20.0 °C at 760 mmHg
Melting Point 26-30 °C(lit.)
Molecular Formula C6H3BrCl2
Molecular Weight 225.898
Flash Point 106.7±11.9 °C
Vapour Pressure 0.1±0.5 mmHg at 25°C
Index of Refraction 1.590
 
Specification:
Appearance:Light yellow liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 1-Bromo-2,4-dichlorobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Dichlorobromobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-2,4-dichlorobenzene Use and application,1-Bromo-2,4-dichlorobenzene technical grade,usp/ep/jp grade.


Related News: “Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself.”(R)-2-Acetoxy-2-phenylacetic acid manufacturer “Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself.”4-methyl-3-nitro-1H-pyridin-2-one supplier The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.(10-(3-(naphthalen-1-yl)phenyl)anthracen-9-yl)boronic acid vendor Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.